Obesity hypertension: the rationale for renin-angiotensin system blockade.
Chan
N N
NN
Qualigenics Diabetes Centre, HKR International Ltd. norman.chan@qualigenics.com
Tong
P C Y
PC
Kong
A P S
AP
Chan
J C N
JC
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
D000959:Antihypertensive Agents